EVO trades 94.8% below Wall Street's consensus target of $3.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EVO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Evotec SE (EVO) has a Wall Street consensus price target of $3.00, based on estimates from 7 covering analysts. With the stock currently trading at $1.54, this represents a potential upside of +94.8%. The company has a market capitalization of $547M.
Analyst price targets range from a low of $2.00 to a high of $4.00, representing a 67% spread in expectations. The median target of $3.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, EVO trades at a trailing P/E of -4.8x. Analysts expect EPS to grow -15.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IQVIQVIA Holdings Inc. | $44.1B | $267.86 | $246.13 | -8.1% | Buy | 20.7x | 45 |
 CRLCharles River Laboratories International, Inc. | $13.4B | $277.33 | $282.36 | +1.8% | Buy | 24.5x | 37 |
 MEDPMedpace Holdings, Inc. | $17.2B | $617.15 | $606.38 | -1.7% | Hold | 35.1x | 19 |
 LSCCLattice Semiconductor Corporation | $16.7B | $121.66 | $162.14 | +33.3% | Buy | 115.8x | 17 |
 RXRXRecursion Pharmaceuticals, Inc. | $1.9B | $3.70 | $5.30 | +43.2% | Hold | — | 10 |
 SDGRSchrödinger, Inc. | $2.2B | $29.23 | $19.00 | -35.0% | Buy | — | 12 |
 ABCLAbCellera Biologics Inc. | $3.8B | $12.31 | $15.33 | +24.5% | Buy | — | 12 |
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
 DHRDanaher Corporation | $155.9B | $221.70 | $223.77 | +0.9% | Buy | 26.1x | 43 |
 ILMNIllumina, Inc. | $38.6B | $255.38 | $210.67 | -17.5% | Buy | 47.7x | 50 |
Quick answers to the most common questions about buying EVO stock.
The consensus Wall Street price target for EVO is $3, representing 94.8% upside from the current price of $1.54. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EVO has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $3 implies 94.8% upside from current levels.
EVO's current price is $1.54 with a consensus target of $3 (94.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $4 for EVO, while the most conservative target is $2. The consensus of $3 represents the median expectation. These targets typically reflect 12-month expectations.
EVO is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EVO stock forecast based on 7 Wall Street analysts shows a consensus price target of $3, with estimates ranging from $2 (bear case) to $4 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on EVO, with a "Buy" consensus rating and $3 price target (94.8% upside). 4 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EVO analyst price targets range from $2 to $4, a 67% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.